DISC-B

**DISC-B** appears to be an internal preclinical discovery code used by Disc Medicine for a selective matriptase-2 inhibitor program. Available public information indicates it inhibits matriptase-2, also known as transmembrane serine protease 6, thereby increasing hepcidin and lowering circulating iron; this mechanism is being explored for disorders of iron overload or ineffective iron regulation. Publicly accessible data are limited to conference and secondary summaries, and no clear evidence was found of a marketed product name, formal generic name, dosage form, or clinical-stage program designation specific to DISC-B.